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A B S T R A C T
Most mammalian cell proliferation assays rely on manual or automated cell counting or the assessment
of metabolic activity in colorimetric assays, with the former being either labor and time intensive or
expensive and the latter being multistep procedures requiring the addition of several reagents. The
proliferation of erythroid cells from hematopoietic stem cells and their differentiation into mature red
blood cells is characterized by the accumulation of large amounts of hemoglobin. Hemoglobin
concentrations are easily quantiﬁable using spectrophotometric methods due to the speciﬁc absorbance
peak of the molecule’s heme moiety between 400 and 420nm. Erythroid proliferation can therefore be
readily assessed using spectrophotometric measurement in this range. We have used this feature of
erythroid cells to develop a simple erythroid proliferation assay that is minimally labor/time- and
reagent-intensive and could easily be automated for use in high-throughput screening. Such an assay can
be a valuable tool for investigations into hematological disorders where erythropoiesis is dysregulated,
i.e., either inhibited or enhanced, into the development of anemia as a side-effect of primary diseases
such as parasitic infections and into cyto-(particularly erythro-) toxicity of chemical agents or drugs.
ã 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
1. Introduction
Erythropoiesis is one of the body’s most productive cell
proliferation processes, yielding an average of 21011 new
erythrocytes from hematopoietic stem cells of the bone marrow
every day to replace those lost to senescence and destruction
[25]. A reduced erythropoietic output or the production of
malfunctioning erythrocytes leads to anemia which can have
severe and even fatal consequences when tissues are insufﬁ-
ciently supplied with oxygen [17]. Homeostasis of erythrocyte
production is primarily regulated by the hormone erythropoietin
(EPO), whose production is upregulated upon tissue oxygen
depletion [9,30]. However, numerous factors – both exogenous
(such as toxins) and endogenous (such as inﬂammatory
cytokines) – can inhibit proliferation and/or differentiation of
erythroid cells [27]. In addition, the requirement for large
amounts of iron for hemoglobinization makes the process highly
dependent on the availability of sufﬁcient concentrations of
transferrin-bound iron [16]. In diseases of chronic inﬂammation
such as rheumatoid arthritis, erythropoiesis is impaired both by
the direct action of proinﬂammatory cytokines such as
tumor necrosis factor (TNF)-a and interferon (IFN)-g and by
upregulation of the liver hormone hepcidin, the primary
regulator of iron uptake and storage, leading to a reduction in
the amount of bio-available iron in circulation [10]. Many
chemotherapeutic agents have also been found to induce anemia
either through an inhibition of the production of EPO or a direct
cytotoxic/inhibitory effect on erythroid cells [6,31].
A number of infections with parasitic agents such as
Plasmodium, Schistosoma, Leishmania or hookworms result in
anemia [22,24]. In the case of intestinal infections, this anemia is
believed to be caused primarily by intestinal hemorrhage, reduced
iron absorption or decreased bioavailability of iron [29].
Inﬂammatory responses to the infections including the secretion
of proinﬂammatory cytokines and/or the resultant upregulation of
hepcidin additionally appear to inhibit erythropoiesis, as in the
anemia of chronic disease [4,27]. In the case of malaria and
leishmaniasis, evidence exists that parasitic products may also
directly impede erythroid proliferation and/or differentiation
[13,33].
On the other hand, erythropoiesis can become dysregulated
in certain myeloproliferative disorders leading to uncontrolled
proliferationoferythroidcells. In theerythroleukemiapolycythemia
vera for example a mutation in the Janus tyrosine kinase
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JAK2 renders erythroid proliferation independent of erythropoietin
and causes excessive red cell production [20,23].
In vitro methods for the generation of erythroid cells from
hematopoietic stem cells derived from various sources have been
established and shown to yield both high proliferation of
erythroid cells and produce functional, mature, enucleated
reticulocytes or erythrocytes, thus faithfully recapitulating the
in vivo process [3,11,12]. In general, the differentiation process of
erythroid progenitor cells and their maturation is characterized
by the acquisition of speciﬁc erythroid features including
particular surface markers, an exit from the cell cycle and the
accumulation of large amounts of hemoglobin that is responsible
for the cells’ ability to bind oxygen [35,39]. A tetramer of 4 globin
chains with a central heme molecule, hemoglobin shows a
spectrophotometric absorbance peak between 400 and 420nm,
which has been exploited for the quantiﬁcation of hemoglobin in
solution by Harboe and others [5,14,15]. As this characteristic can
be used for hemoglobin quantiﬁcation not only in solution but
also when cell-bound, we have developed a spectrophotometric
assay for assessing erythroid proliferation based on absorbance
at 405nm.
2. Materials and methods
All chemicals were obtained from Sigma–Aldrich (Arklow,
Ireland) unless stated otherwise.
2.1. Cell isolation
Mononuclear cells (MNC) were isolated from peripheral blood
buffy coats obtained from the Irish Blood Transfusion Services
(Dublin, Ireland) using density gradient centrifugation with
histopaque-1077. CD34+ cells were isolated from mononuclear
cells via immuno-magnetic separation using anti-CD34 magnetic
beads according to the manufacturer’s instructions (Miltenyi
Biotec, Bisley, UK).
2.2. Cell culture
Cultures were initiated from frozen or freshly isolated
mononuclear cells or CD34+ cells. For depletion of leukocytes,
mononuclear cells were pre-cultured for 2 days in IMDM with
stabilized glutamine (Biochrom, Berlin, Germany) containing 5%
(vol/vol) heparinized human plasma and 3U/ml EPO (Janssen-
Cilag, Dublin, Ireland). Cells were then washed and cultured in
erythroid proliferation medium [12] consisting of IMDM with
330mg/ml iron-saturated human transferrin and 10mg/ml
recombinant human insulin, supplemented with 5% heparinized
human plasma, 100 ng/ml stem cell factor (SCF) (Cambridge
Biosciences, Cambridge, UK), 5 ng/ml interleukin-3 (IL-3) (R&D
Systems, Minneapolis, MN, USA), 3U/ml EPO and 106M
hydrocortisone for 1–2 days. CD34+ cells were plated directly
into the appropriate conditions. Manual cell counting was
performed using the trypan blue exclusion method with trypan
blue diluted 1/6 in phosphate buffered saline (PBS) and added to
cells at 1:1 or 1:4 ratios.
2.3. Plasmodium falciparum conditioned medium
P. falciparum-conditioned medium was obtained from blood-
stage cultures of P. falciparum 3D7 cultures grown in RPMI
medium supplemented with 5% (wt/vol) Albumax1 in a candle
jar according to published methods [8]. P. falciparum cultures
were grown to 10–15% parasitemia, washed two times with
wash medium consisting of RPMI supplemented with 0.18 g/l
sodium bicarbonate and one time with IMDM and then
resuspended in IMDM. For higher protein content, cultures
were concentrated 6–8 fold by resuspension in lower volumes
of IMDM after washing and cultured for 3–4h to obtain
conditioned medium. Conditioned medium was obtained by
centrifuging the culture supernatant for 10min at 2000 rpm
(823 g) followed by ﬁltration through a 0.2mm ﬁlter and used
at up to 80% (vol/vol) in erythroid medium.
2.4. Absorbance-based assay
Cells (CD34+ cells or pre-cultured MNCs) were subsequently
seeded in erythroid proliferation medium containing 5% hepa-
rinized human plasma, 100 ng/ml SCF, 5 ng/ml IL-3 and 3U/ml
EPO as standard conditions. These conditions served as a positive
control for erythroid proliferation. As a negative control, cells
were seeded in pure IMDM medium lacking growth factors and
plasma. Erythropoiesis inhibiting agents were added at different
concentrations or growth factor concentrations were varied to
assess the effect on erythroid proliferation. Cells were seeded in
96-well ﬂat-bottom plates at 1–5105 cells/ml and cultured in a
humidiﬁed incubator at 37 C and 5% CO2 for up to 21 days. All
conditions were set up in triplicate and for each condition a well
containing the appropriate medium blank without cells was
included.
Absorbance measurements of plates with lid were taken at
405nm using a Synergy H1 (Biotek, Potton, UK) plate reader
preheated to 37 C and following 2min of linear shaking at
567 cycles per minute (cpm).
2.5. Analysis
Results from manual cell counting were determined as the
mean and standard deviation of the cell concentrations of
triplicate wells.
Results from spectrophotometric measurements were deter-
mined as the mean absorbance of triplicate wells and their
standard deviation. The mean values were corrected by the
absorbance of the medium blank and presented as percentage of
the positive control. Statistical analysis was performed using Prism
software (La Jolla, CA, USA).
3. Results
3.1. Method principle
The Harboe method has been established for determining
hemoglobin concentrations in solution using spectrophotometric
measurement at 415nm and has been validated for assessing
hemolysis in red cell samples [14,15]. We adapted this method for
estimating erythroid cell concentrations in unlysed culture
samples and determining erythroid proliferation in a non-
invasive manner. Hemoglobin shows maximum light absorption
between 400 and 420nm and we found absorbance at 405nm and
415nm to correlate linearly (R2 = 0.9999) allowing the use of
405nm absorbance ﬁlters commonly available on standard plate
readers (Fig.1a).We established that the lysis of erythrocytes is not
necessary for reliable hemoglobin quantiﬁcation and that cell
suspensions could be directly subjected to spectrophotometric
measurement (Fig. 1b, R2 = 0.9905). Initial assay set-up was
performed using samples of native erythrocytes isolated from
donor blood suspended in PBS and absorbance measurements at
405nm were found to correlate linearly (R2 = 0.998) with manual
cell counts (Fig. 1c). Using the function obtained from the linear ﬁt
of such an erythrocyte standard curve using GraphPad software,
cultures could be expressed as ‘erythrocyte equivalents’ based on
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their absorbance (erythrocyte equivalents/ml = (5,413,000
91,210)A405 (154,70080,730)).
Absorbance measurements were obtained from in vitro
erythroid cultures at various time points of culture using a plate
reader pre-heated to 37 C, and plates were agitated to disperse
cells evenly in the microwells before measurement. The
absorbance values were corrected using the absorbance of the
medium of each condition and normalized to a positive control
culture on the same plate to determine the hemoglobinization as
percentage of the positive control that in turn correlated with the
cell expansion (Fig. 2).
3.2. Stability
Hemoglobinization begins at the proerythroblast stage and
two thirds of a cell’s total hemoglobin are produced by
the erythroblast while the remaining third is synthesized at
the reticulocyte stage [35]. In culture, cells contained detectable
amounts of hemoglobin from day 8 after seeding into erythroid
medium, showed strong increase in hemoglobinization over the
next 7 days and reached a plateau thereafter. Absorbance
measurements based on hemoglobin remained stable over
extended periods of time showing only slight decreases in
[(Fig._2)TD$FIG]
Fig. 2. Outline of set-up and measurement principle of spectrophotometric erythroid proliferation assay. MNC=mononuclear cell.
[(Fig._1)TD$FIG]
Fig. 1. (a–c) Hemoglobin measurement at 405nm can be used to determine the cell concentrations of unlysed samples of erythrocytes: (a) hemoglobin absorbance of
erythrocyte lysates at 415 and 405nm correlated linearlywith each other. (b) The absorbances at 405nmof unlysed erythrocyte samples showed linear correlationwith those
of erythrocytes lysed osmotically in distilled water. (c) The concentrations of erythrocyte samples as determined by manual counting using trypan blue correlated linearly
with absorbance measurements at 405nm. Dilutions of native erythrocytes in PBS were used between 1105 and 1107 cells/ml; results are shown as mean and standard
deviation of triplicate determinations.
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absorbance after further 10 days (Fig. 3), indicating that this
molecule is not readily degraded evenwhen it is released into the
culture supernatant upon cell death and rupture.
3.3. Optimization of culture conditions
Cell concentrations and absorbance measurements for ery-
throid cultures correlated linearly and while standard deviations
were larger than for native red blood cell samples, these varied
comparably for both measurement principles due to higher
biological variation between triplicate wells. The linear function
obtained for a culture at day 15 of erythroid culture (Fig. 4b)
indicated a lower absorbance for a given cell concentration than
obtained for the erythrocyte standard curve as these erythroid cells
had not yet fully hemoglobinized. While the ex vivo culture
method does not yield fully mature erythrocytes but produces
predominantly reticulocytes, a linear correlation between cell
concentrations and absorbance could be demonstrated not only for
[(Fig._4)TD$FIG]
Fig. 4. (a and b) Optimization of cultivation conditions: (a) the effect of different growth factor (EPO, SCF) and plasma (PP) concentrations on erythroid proliferation could be
determined using the spectrophotometric erythroid proliferation assay. The positive control was grown in standard conditions of 5% plasma, 100ng/ml SCF, 5 ng/ml IL-3 and
3U/ml EPO. Concentrations of plasma, SCF or EPO were varied individually while the other factors were maintained at standard concentrations. Results are the mean
and standard deviation of triplicates expressed as percentage of positive control. (b) The assay could distinguish between conditions promoting or inhibiting erythroid
proliferation equally well as manual cell counting, showing linear correlation (R2 = 0.9313) between the cell concentration and the absorbance of respective samples. Results
are shown as mean and standard deviation of triplicate determinations on day 15 of culture.
[(Fig._3)TD$FIG]
Fig. 3. Signal stability: hemoglobinization increased strongly between days 8 and
15 in erythroid culture and hemoglobin absorbance showed high stability for up to
20 days thereafter in cultures containing high growth (pos. control = optimal
growth conditions), medium growth (condition X= suboptimal growth conditions)
and very low growth (neg. control = cultivationwithout growth factors). Results are
presented as mean and standard deviation of triplicate determinations.
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mature erythrocytes (Fig. 1c) but also for ex vivo generated
erythroid cells which represent a mixed population of erythroid
cells of different maturities. Comparisonwith the internal positive
control (standard growth conditions) thus allowed for a determi-
nation of reduced or enhanced erythroid proliferation. Using this
method, culture conditions which are less favorable to erythroid
expansion, e.g., reduced concentrations of plasma or of the growth
factors stem cell factor (SCF) or EPO in the erythroidmedium, could
be determined (Fig. 4a and b).
3.4. Erythroid inhibition by P. falciparum
Using this method, we were furthermore able to detect
erythropoiesis inhibiting activity in medium conditioned by
blood-stage cultures of the malarial parasite P. falciparum. The
assay was able to distinguish between erythropoiesis-inhibiting
and -promoting conditions to the same extent as manual cell
counting using trypan blue exclusion (Fig. 5a) and was able to
detect differential responses to different concentrations of the
inhibitory medium (Fig. 5b).
3.5. Cytotoxic agents
Dimethylsulfoxide (DMSO) is a commonly used solvent for
drugs that show limited solubility in aqueous solutions but it
effects a range of biological functions and can cause toxic side
effects in vivo [37]. DMSO is also used as the primary cryoprotec-
tive agent for hematopoietic stem cells for transplantation as it
reduces cell damage due to crystal formation and protects cells
from dehydration. It has, however, been shown to be toxic to these
cells at elevated concentrations resulting in around 25% of viable
cell loss at 5% (vol/vol) DMSO and up to 50% at 10% DMSO [1].
DMSO therefore presents a useful candidate molecule for
evaluating the potential of this assay for the assessment of
chemical cytotoxicity. High concentrations (20% and 10%) abrogat-
ed all cell growth and very low levels of hemoglobin formation
were detected at 5% and 2% DMSO whereas concentrations below
1% showed no inhibition (Fig. 6a). The applicability of the assay for
toxicological studies was further demonstrated by the use of the
antibiotic chloramphenicol which has been found to cause bone
marrow suppression and aplastic anemia in vivo [34]. Using our in
vitro system, concentration-dependent inhibition of erythroid
growth was observed, with a 1mg/ml concentration of the drug
almost abolishing erythropoiesis whereas 12.5mg chlorampheni-
col/ml still caused about 50% growth reduction (Fig. 6b). The
suitability of an assay for high-throughput screening (HTS)
depends on its performance and sensitivity which can be assessed
using a number of statistical parameters including the Z0 factor
commonly used to quantify the quality of an assay [19]. In a total of
10 different assays that were validated, our spectrophotometric
erythroid proliferation assay performedwell within the acceptable
limits and showed an average Z0 of 0.67 (Table 1).
4. Discussion
Erythropoiesis is one of the body’s most proliferative cell
production processes and dysregulation of this process can
have life-threatening consequences. In the absorbance based
erythroid proliferation assay presented here, we exploit the
features of erythroid cultures – high cell expansion in vitro and
accumulation of large amounts of spectrophotometrically
quantiﬁable hemoglobin – to develop a novel research tool.
Research continues into the development of suitable drug
treatments for erythroleukemias such as polycythemia vera (PV).
These drugs currently include hydroxycarbamide (hydroxyurea),
pipobroman or interferon, but these therapies can increase the risk
of transformation to myeloﬁbrosis or leukemia [21,26]. An
erythroid proliferation assay based on PV hematopoietic stem
cells could therefore signiﬁcantly facilitate the screening for novel
compounds that reduce erythroid proliferation to normal levels in
this type of myeloproliferative disorder. As venesection in an
attempt to lower hematocrit levels is one of the primary
treatments for PV, mononuclear cells from PV patients would be
readily available from these phlebotomies and a patient’s own cells
could even be used to test for responsiveness to speciﬁc drug
treatments.
On the other hand, such screening may enable identiﬁcation of
erythropoiesis stimulating agents in conditions where the process
is inhibited such as those of Diamond Blackfan anemia, a
congenital hypoplastic anemia characterized by mutations in
genes encoding ribosomal proteins leading to reduced production
of erythrocytes [7].
Anemic conditions where erythroid inhibition may be a direct
result of the action of inhibitory pathogen-derived factors as
suspected inmalaria [2] or Leishmania infections could also beneﬁt
from a screening tool for the identiﬁcation of the causative factors
and methods of their inactivation.
Finally, drug cytotoxicity studies – and erythrotoxicity of cancer
chemotherapeutics in particular – may be signiﬁcantly facilitated
by a high-throughput assay, reducing the need for animal models
and cutting both time and cost requirements. A number of
[(Fig._5)TD$FIG]
Fig. 5. (a and b) Erythroid inhibition by products of P. falciparum: (a) absorbance
measurement and manual cell counting could distinguish between conditions
promoting erythroid proliferation (containing optimal concentrations of growth
factors [100ng/ml SCF, 5 ng/ml IL-3, 3U/ml EPO] and medium [5% plasma]) or
reducing erythroid proliferation (medium conditioned with products of P.
falciparum). Results are presented as mean and standard deviation of triplicate
determinations. (b) Erythroid proliferationwas affected by different concentrations
of two different batches (a and b) of P. falciparum conditioned medium (Pf-CM).
Results are the mean and standard deviation of triplicates expressed as percentage
of positive control.
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cytotoxicity assays are commercially available and have been used
for high-throughput screening. Most of these are colorimetric or
ﬂuorescent assays that rely on either the measurement of enzyme
activities in viable cells or detect enzymes released into culture
supernatants upon cell death using established cell lines [28,40].
Among the most common assays are those based on the
measurement of activities of ATP, lactate dehydrogenase (LDH),
aminopeptidase, or proteases, or determination of redox potential
via resazurin or tetrazolium based compounds (MTT, MTS, XTT).
While many of the aforementioned assays have established track
records for cytotoxicity studies, their limitation lies in the
requirement for the addition of reagents making them both more
cost and labor-intensive and preventing continuous measurement
of a culture. Recent advances in drug cytotoxicity testing include
Table 1
Assay performance: evaluation of standard parameters using the mean (m) and standard deviation (s) of the positive (max= standard erythroid growth conditions) and
negative control (min =no growth factors) shows good assay performance and sensitivity for the spectrophotometric assay when used to analyze the effect of DMSO,
chloramphenicol and in a total of 10 different assays. Results are calculated using the given equations and the average assay performance is shown as mean and standard





Average of n =10 assays
day 101.5 (7–12)
Acceptable limits
Coefﬁcient of variation (max)
%CV=smax/mmax100
7.6% 5.4% 6.02.6% (2.5–9.9%) <15%
Coefﬁcient of variation (min)
%CV=smin/mmin100
11.6% 11.3% 10.55.4% (0–17.2%) <15%
Signal to noise ratio
S:N= (mmaxmmin)/smin
17.8 49.1 34.116.5 (14.3–63.8)
Signal to background ratio
S:B =mmax/mmin
3.1 6.5 4.61.1 (3.1–6.5) >2-fold
Signal window
SW= (mmaxmmin3(smin +smin))/smax
4.4 11.7 9.94.6 (4–17.4) >2-fold
Z0 factor
Z0 = (3smax + 3smin)/|mmaxmmin|
0.49 0.75 0.670.11 (0.49–0.86) >0.5
[(Fig._6)TD$FIG]
Fig. 6. (a and b) Determination of cytotoxicity using hemoglobin-based absorbance assay: (a) DMSO strongly inhibited erythropoiesis at concentrations higher than 2%.
(b) Chloramphenicol (Cm) reduced erythroid proliferation in a concentration-dependent manner whereas this effect was not seen by the ethanol (EtOH) solvent control.
Results are the mean and standard deviation of triplicates expressed as percentage of positive control.
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the development of microﬂuidic cell culture systems or
‘lab-on-a-chip’ devices [36,38]. These devices have the advantage
of allowing non-invasive and continuous monitoring but are more
complex and costly in terms of equipment.
Automation of the spectrophotometric assay described here
should be easily achievable through an adaptation to common
microplate-handling robotic set-ups. While an internal positive
control to which results are normalized reduces the need for
plate-to-plate standardization, this could nonetheless be
facilitated, e.g., for cytotoxicity studies of candidate drugs, by
establishing large MNC pools or using erythroleukemia cell lines.
A limiting factor to the use of a hemoglobin-based assay for
cytotoxicity studies is however its inability to distinguish between
live and dead cells, as it can only determine effects on the growth/
hemoglobinization of erythroid cells but cannot detect the death of
already fully hemoglobinized cells. Hemoglobinization continues
past the stagewhere erythroid cells become cell cycle arrested and
cease proliferating and large amounts of hemoglobin are still
synthesized at the reticulocyte stage [35]. The assay is thus able to
detect cytotoxic effects on erythroid cells during growth phase, as
hemoglobinization would cease prematurely, but unable to
differentiate between intact highly hemoglobinized reticulocytes
and hemoglobin which may have been released into solution by
lysed cells in late stages of culture.
The spectrophotometric assay has been successfully used for
the detection of erythropoiesis inhibiting activity in medium from
P. falciparum cultures and to determine preferential growth factor
concentrations for erythroid expansion. It can further detect
cytotoxic components and react in a concentration-responsive
manner. Overall, this method provides the means for rapid
assessment of erythroid proliferation – either enhanced or
inhibited – compared to a standard control and can thus be highly
beneﬁcial in initial screening stages to select potential conditions
or candidatemolecules of interest. Design of experiment (DoE) has
been growing in signiﬁcance for process optimization and drug
design applications [18,32]. Coupling DoE for erythroid systems
with an automatable assay such as this one to obtain the
experimental results on which to build the design and verify its
prediction could allow for the acquisition of large amounts of data
in short periods of time. For an assay to be implementable in high-
throughput screening it has to meet a number of criteria: it should
be simple, automatable, show sensitive and reproducible
performance and last but not least be economically feasible. We
believe this assay fulﬁlls all of these criteria and presents a good
candidate for HTS.
Few cells in the human body lend themselves to the
establishment of a colorimetric proliferation assay as readily as
erythroid cells which simply produce the red read-out dye
themselves – the next step is developing the applications.
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